Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the endocrinology drugs market grown in recent years?

In the past few years, there has been a notable expansion in the market size of endocrinology drugs. This market is projected to increase from $33.26 billion in 2024 to $36.21 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.86%. The historical growth of this sector is linked to a variety of factors, such as the rising global occurrence of diabetes, higher government initiatives, increased healthcare spending, growing prevalence of adrenal gland disorders, heightened demand for insulin analogs, and an increased volume of endocrinologists.

How is the endocrinology drugs market size expected to evolve during the forecast period?

We can anticipate robust expansion in the endocrinology drugs market in the approaching years. With a compound annual growth rate (CAGR) of 8.60%, the market will escalate to a value of $50.37 billion by 2029. The predicted growth during this period is largely due to factors such as the rise in the diabetic populace, increased incidence of endocrine disorders, an upsurge in adolescents suffering from hormonal irregularities, and escalating obesity levels. Key trends that are projected to influence the market during the forecast period encompass technological evolution, the utilization of sophisticated drug delivery systems, integration of digital healthcare solutions, precision medicine, and combination therapies.

Get your endocrinology drugs market report here!

https://www.thebusinessresearchcompany.com/report/endocrinology-drugs-global-market-report

Which key drivers are propelling the endocrinology drugs market’s growth?

The escalation in the occurrence of endocrine diseases is poised to boost the advancement of the endocrinology drugs market. Endocrine disorders, diseases that wreak havoc on the endocrine system, lead to hormonal imbalances or malfunctions in hormone regulation which can cause perturbations in ordinary bodily operations. The mounting prevalence of such diseases is attributable to a variety of factors such as alterations in lifestyle, an aging populace, and advancements in diagnosis, all of which have resulted in the increased awareness and frequency of these conditions. By managing hormone levels, addressing issues in the glands, and re-establishing hormonal equilibrium, endocrinology drugs can alleviate the symptoms and enhance overall health. For example, the National Library of Medicine, a medical library based in the USA, reported in May 2023 that approximately 13 million people in the USA, equivalent to 4.78% of the population, are grappling with undetected endocrine disorders. Thyroid disease, which accounts for around 30% to 40% of patients treated for endocrine disorders, is one of the most common. Consequently, the escalating prevalence of endocrine diseases is fuelling progress in the endocrinology drugs market.

What are the market segments in the endocrinology drugs industry?

The endocrinology drugs market covered in this report is segmented –

1) By Indication: Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications

2) By Therapy Area: Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Others Therapy Areas

3) By Distribution Channel: Hospital pharmacies, Online Pharmacies, Retail pharmacies

4) By End User: Hospitals, Ambulatory Surgical Centers, Others End Users

Subsegments:

1) By Hyperthyroidism: Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers

2) By Hypothyroidism: Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies

3) By Diabetes: Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors

4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens

5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists

6) By Pituitary Gland Disorders: Somatostatin Analogs, Gonadotropins, Dopamine Agonists

7) By Other Indications: Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20769&type=smp

Which leading companies are shaping the growth of the endocrinology drugs market?

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited

What key trends are currently impacting the endocrinology drugs market’s development?

Major companies operating in the endocrinology drugs market are focusing on developing innovative products such as ready-to-use vials to improve medication administration. Ready-to-use vials are pre-filled and pre-dosed medication containers that require no reconstitution or preparation before administration. For instance, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Levothyroxine sodium injection in ready-to-use vials at a concentration of 100 mcg/mL. The formulation is designed for immediate use, eliminating the need for reconstitution and reducing the risk of preparation errors, thereby improving patient safety. It provides precise and consistent dosing, which is critical for managing conditions like hypothyroidism and myxedema coma. The ready-to-use vials also improve efficiency for healthcare providers, saving time and ensuring accurate administration in urgent care settings.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20769

Which geographic areas are influencing the growth of the endocrinology drugs market?

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Radiopharmaceuticals Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/radiopharmaceuticals-global-market

Pancreatic Cancer Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Global Pancreatic Cancer Drugs Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: